- Molecular NamePregabalin
- Synonympregabalin
- Weight159.229
- Drugbank_IDDB00230
- ACS_NO148553-50-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.92
- pka4.2; 10.6
- LogD (pH=7, predicted)-0.92
- Solubility (experiment)Freely soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.28
- LogSw (predicted, AB/LogsW2.0)54.11
- Sw (mg/ml) (predicted, ACD/Labs)82.6
- No.of HBond Donors3
- No.of HBond Acceptors3
- No.of Rotatable Bonds5
- TPSA63.32
- StatusFDA approved
- AdministrationOral(main), IV, Insufflation
- PharmacologyAn anticonvulsant drug used for neuropathic pain and as an adjunct therapy for partial seizures with or without secondary generalization in adults.
- Absorption_value90.0
- Absorption (description)Well absorbed after oral administration.
- Caco_2N/A
- Bioavailability90.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNegligible
- Half life5~6.5 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn clinical trials of all patient populations combined, dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and "thinking abnormal" (primarily difficulty with concentration/attention) were more commonly reported by subjects treated with LYRICA than by subjects treated with placebo (≥ 5% and twice the rate of that seen in placebo).
- LD50 (rat)N/A
- LD50 (mouse)N/A